Previous studies have shown that HER2-low tumors (especially those scored as IHC 2+) have stronger heterogeneity [27, 28], and HER2-low can be found in both hormone receptor-positive and triple-negative breast cancers [29]. Here, ERBB2 is linked to triple-negative breast carcinoma.